NCT03653507 2026-04-17
GLOW
Astellas Pharma Inc
Phase 3 Active not recruiting
Clinical Trials
17 trialsNCT05152147 2026-04-17
HERIZON-GEA-01
Jazz Pharmaceuticals
Phase 3 Active not recruiting
NCT04661150 2026-04-16
A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT07529613 2026-04-14
T-DXd_HER2Low
National Cancer Center Hospital East
Phase 1/2 Completed
NCT07431281 2026-04-13
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
AstraZeneca
Phase 3 Recruiting
NCT04745988 2026-04-09
An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib With Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients With Gastric Cancer
National Cancer Center Hospital East
Phase 2 Active not recruiting
NCT05567835 2026-04-09
TOGAR
Baylor College of Medicine
Phase 2 Terminated
NCT05184803 2026-04-07
A Phase 2 Study of Neoadjuvant Docetaxel, Oxaliplatin, S-1 in Patients With Unresectable Locally Advanced or Distant Metastasis Limited to Lymph Node Gastric Cancer
Asan Medical Center
Phase 2 Recruiting
NCT06131840 2026-04-07
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Seagen Inc.
Phase 1 Recruiting
NCT07283939 2026-04-07
Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
Alliance for Clinical Trials in Oncology
Phase NA Recruiting
NCT07515625 2026-04-07
Efficacy of Sintilimab Combined With Bevacizumab and XELOX/SOX in Initially Unresectable AFP-positive Gastric/Gastroesophageal Junction Adenocarcinoma
Fudan University
Phase 2 Not yet recruiting
NCT03505320 2026-04-03
ILUSTRO
Astellas Pharma Inc
Phase 2 Active not recruiting
NCT05568095 2026-04-02
STAR-221
Arcus Biosciences, Inc.
Phase 3 Active not recruiting
NCT05891171 2026-03-31
ARC-25
Arcus Biosciences, Inc.
Phase 1 Active not recruiting
NCT02366819 2026-03-30
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
University of Chicago
Phase 4 Suspended
NCT05329766 2026-03-30
EDGE-Gastric
Arcus Biosciences, Inc.
Phase 2 Active not recruiting
NCT07492615 2026-03-25
A Clinical Study of Sintilimab Combined With Chemothrapy Versus Chemotherapy as Adjuvant Therapy for Gastric/Gastroesophageal Junction Adenocarcinoma
Fudan University
Phase 2 Recruiting